PMID- 2666593
OWN - NLM
STAT- MEDLINE
DCOM- 19890829
LR  - 20190908
IS  - 0167-594X (Print)
IS  - 0167-594X (Linking)
VI  - 7
IP  - 1
DP  - 1989 May
TI  - The potential role of lonidamine (LND) in the treatment of malignant glioma. 
      Phase II study.
PG  - 103-8
AB  - Up-to-date unsatisfactory results obtained in multimodality treatments of 
      malignant glioma have prompted the research of new therapeutic modalities with 
      'unconventional' modes of action. Lonidamine (LND) is a drug which reduces 
      aerobic glycolytic activity in both human and experimental tumors. This effect 
      mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which 
      is present in large amounts in malignant cells. A Phase II study was conducted on 
      patients with recurrent glioma; 12 patients were admitted to the study. Clinical 
      side effects were moderate, necessitating a reduction of the dosage in only 1 
      case. The objective results were evaluated according to the indications of Levin. 
      2 responders and 3 cases of stable disease were observed out of 10 evaluable 
      patients. The potential value of this new drug is discussed.
FAU - Carapella, C M
AU  - Carapella CM
AD  - Regina Elena Institute for Cancer Research, Rome, Italy.
FAU - Paggi, M G
AU  - Paggi MG
FAU - Cattani, F
AU  - Cattani F
FAU - Ciottoli, G B
AU  - Ciottoli GB
FAU - Floridi, A
AU  - Floridi A
FAU - Iandolo, B
AU  - Iandolo B
FAU - Raus, L
AU  - Raus L
FAU - Riccio, A
AU  - Riccio A
FAU - Caputo, A
AU  - Caputo A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indazoles)
RN  - 0 (Pyrazoles)
RN  - U78804BIDR (lonidamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/mortality/secondary
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glioma/*drug therapy/mortality/secondary
MH  - Humans
MH  - Indazoles/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/secondary
MH  - Pyrazoles/*therapeutic use
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1007/BF00149384 [doi]
PST - ppublish
SO  - J Neurooncol. 1989 May;7(1):103-8. doi: 10.1007/BF00149384.